BIOCORP acquired by NOVO NORDISK

The acquisition of Biocorp by Novo Nordisk, achieved through the purchase of Bio Jag's 45.3% stake and a subsequent mandatory public tender offer, marks a significant shift in strategy, transitioning from a collaborative research and development model to a proprietary technology platform. Having previously mitigated risks associated with the Mallya technology through regulatory approvals and commercial validation, including agreements with prominent industry players such as Sanofi and Roche Diabetes Care, Biocorp's management had laid the groundwork for this transaction. By assuming full ownership, Novo Nordisk gains control over a crucial component of its supply chain, securing exclusive access to a key connectivity solution for pen injectors. Under the continued leadership of CEO Éric Dessertenne, the integration process prioritizes the expansion of physical assets, notably the launch of an enlarged manufacturing facility in Issoire, aimed at increasing production capacity. The growth strategy following the acquisition is centered on leveraging Novo Nordisk's extensive global distribution network to deploy connected delivery systems on a large scale, while repurposing the French manufacturing hub as a specialized development center for next-generation digital monitoring devices across a broader range of therapeutic areas, with plans to enter new markets and expand product offerings.